James T. Parsons - Jun 1, 2024 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Role
Director
Signature
/s/ Amy E. Culbert, attorney-in-fact
Stock symbol
DMAC
Transactions as of
Jun 1, 2024
Transactions value $
$0
Form type
4
Date filed
6/3/2024, 04:21 PM
Previous filing
Jan 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding DMAC Voting Common Shares, no par value per share 59.9K Jun 1, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAC Stock Option (right to buy) Award $0 +28.5K $0.00 28.5K Jun 1, 2024 Common Shares 28.5K $2.90 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 3,850 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan and 53,837 shares issuable upon settlement of deferred stock units granted under the DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan, as amended from time to time.
F2 Vests in four nearly equal quarterly installments over one year.